James Cavet

2.7k total citations · 1 hit paper
18 papers, 1.6k citations indexed

About

James Cavet is a scholar working on Hematology, Oncology and Immunology. According to data from OpenAlex, James Cavet has authored 18 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hematology, 6 papers in Oncology and 6 papers in Immunology. Recurrent topics in James Cavet's work include Multiple Myeloma Research and Treatments (10 papers), Hematopoietic Stem Cell Transplantation (8 papers) and Cancer Treatment and Pharmacology (4 papers). James Cavet is often cited by papers focused on Multiple Myeloma Research and Treatments (10 papers), Hematopoietic Stem Cell Transplantation (8 papers) and Cancer Treatment and Pharmacology (4 papers). James Cavet collaborates with scholars based in United Kingdom, United States and Australia. James Cavet's co-authors include Peter G. Middleton, Anne M. Dickinson, Alex Molassiotis, Barbara A. Wilson, Susan Blair, Graham Jackson, Jean‐Luc Harousseau, Stella M. Davies, Grigoriy Rekhtman and Halyna Pylypenko and has published in prestigious journals such as The Journal of Experimental Medicine, Blood and The Lancet Oncology.

In The Last Decade

James Cavet

17 papers receiving 1.5k citations

Hit Papers

Subcutaneous versus intravenous administration of bortezo... 2011 2026 2016 2021 2011 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
    2011 661 citations Philippe Moreau, Halyna Pylypenko et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
James Cavet United Kingdom 10 978 622 546 446 144 18 1.6k
Georgia Schilling Germany 18 610 0.6× 472 0.8× 443 0.8× 329 0.7× 93 0.6× 62 1.3k
Karel Hählen Netherlands 17 535 0.5× 389 0.6× 959 1.8× 447 1.0× 197 1.4× 31 2.1k
Lone Smidstrup Friis Denmark 16 744 0.8× 281 0.5× 348 0.6× 366 0.8× 230 1.6× 43 1.4k
Ashley Rosko United States 20 584 0.6× 713 1.1× 461 0.8× 110 0.2× 106 0.7× 122 1.4k
Shiann‐Tarng Jou Taiwan 24 541 0.6× 355 0.6× 516 0.9× 357 0.8× 498 3.5× 118 1.9k
Michael Koenigsmann Germany 20 405 0.4× 436 0.7× 227 0.4× 296 0.7× 185 1.3× 63 1.5k
Kenneth R. Meehan United States 18 337 0.3× 576 0.9× 187 0.3× 355 0.8× 87 0.6× 70 1.1k
Shelly Carter United States 18 1.5k 1.5× 433 0.7× 168 0.3× 661 1.5× 542 3.8× 25 2.1k
Sang Kyun Sohn South Korea 20 309 0.3× 360 0.6× 305 0.6× 110 0.2× 118 0.8× 61 1.2k
Deborah Marcellus United States 19 491 0.5× 555 0.9× 126 0.2× 251 0.6× 240 1.7× 30 1.2k

Countries citing papers authored by James Cavet

Since Specialization
Citations

This map shows the geographic impact of James Cavet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Cavet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Cavet more than expected).

Fields of papers citing papers by James Cavet

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Cavet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Cavet. The network helps show where James Cavet may publish in the future.

Co-authorship network of co-authors of James Cavet

This figure shows the co-authorship network connecting the top 25 collaborators of James Cavet. A scholar is included among the top collaborators of James Cavet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Cavet. James Cavet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
2.
Brooks, Nigel, Fabio M. R. Amaral, Neil Pegg, et al.. (2022). Potent Pre-Clinical and Early Phase Clinical Activity of EP300/CBP Bromodomain Inhibitor CCS1477 in Multiple Myeloma. Blood. 140(Supplement 1). 852–853. 6 indexed citations
3.
Kulkarni, Samar, John Murray, Mike Dennis, et al.. (2021). Use of Cryopreserved Allogeneic PBSC Results in Delayed Engraftment and Increased Incidence of Poor Graft Function. Blood. 138(Supplement 1). 1778–1778.
4.
Fiorenza, Salvatore, Michael Shipton, Simon J. Harrison, et al.. (2019). Time from autologous to allogeneic hematopoietic stem cell transplantation impacts post-transplant outcomes in multiple myeloma. Bone Marrow Transplantation. 55(6). 1172–1174. 4 indexed citations
5.
Schey, Steve, Sarah Brown, Kwee Yong, et al.. (2015). Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial. British Journal of Haematology. 170(3). 336–348. 16 indexed citations
6.
Rhee, Frits van, Margaret Rothman, Kai Fai Ho, et al.. (2015). Patient-reported Outcomes for Multicentric Castleman’s Disease in a Randomized, Placebo-controlled Study of Siltuximab. Patient. 8(2). 207–216. 20 indexed citations
7.
8.
Moreau, Philippe, Halyna Pylypenko, Sebastian Grosicki, et al.. (2011). Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. The Lancet Oncology. 12(5). 431–440. 661 indexed citations breakdown →
9.
Molassiotis, Alex, et al.. (2010). Unmet supportive care needs, psychological well‐being and quality of life in patients living with multiple myeloma and their partners. Psycho-Oncology. 20(1). 88–97. 202 indexed citations
10.
Moreau, Philippe, Halyna Pylypenko, Sebastian Grosicki, et al.. (2010). A Phase 3 Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib In Patients with Relapsed Multiple Myeloma. Blood. 116(21). 312–312. 5 indexed citations
11.
Parrish, Christopher, Amin Rahemtulla, James Cavet, et al.. (2010). The Role of High Dose Chemotherapy and Autologous Stem Cell Transplantation In Patients with Multiple Myeloma Refractory to Initial Induction Therapy. Blood. 116(21). 1341–1341. 1 indexed citations
12.
Molassiotis, Alex, et al.. (2009). Living with multiple myeloma: experiences of patients and their informal caregivers. Supportive Care in Cancer. 19(1). 101–111. 89 indexed citations
13.
Collin, Matthew, Derek N.J. Hart, Graham Jackson, et al.. (2006). The fate of human Langerhans cells in hematopoietic stem cell transplantation. The Journal of Experimental Medicine. 203(1). 27–33. 97 indexed citations
14.
Cullup, Hannah, Anne M. Dickinson, James Cavet, Graham Jackson, & Peter G. Middleton. (2003). Polymorphisms of interleukin‐1α constitute independent risk factors for chronic graft‐versus‐host disease after allogeneic bone marrow transplantation. British Journal of Haematology. 122(5). 778–787. 48 indexed citations
15.
Dickinson, Anne M., James Cavet, Hannah Cullup, et al.. (2002). Predicting outcome in hematological stem cell transplantation.. PubMed. 50(6). 371–8. 2 indexed citations
16.
Cavet, James, Anne M. Dickinson, Jean Norden, et al.. (2001). Interferon-γ and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Blood. 98(5). 1594–1600. 187 indexed citations
17.
18.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Georgia Schilling Breakdown of academic impact, for papers by Karel Hählen Breakdown of academic impact, for papers by Lone Smidstrup Friis Breakdown of academic impact, for papers by Ashley Rosko Breakdown of academic impact, for papers by Shiann‐Tarng Jou Breakdown of academic impact, for papers by Michael Koenigsmann Breakdown of academic impact, for papers by Kenneth R. Meehan Breakdown of academic impact, for papers by Shelly Carter Breakdown of academic impact, for papers by Sang Kyun Sohn Breakdown of academic impact, for papers by Deborah Marcellus
Rankless by CCL
2026